EUVIMEDEUVIMED entdecken
Open Access

Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma

David G Su iD, Dijana Djureinovic, David Schoenfeld iD, Bernadette Marquez-Nostra iD, Kelly Olino iD, Lucia Jilaveanu, Harriet Kluger iD

JCO Precision Oncology · 2024-04 · (8)

DOI: 10.1200/po.23.00702 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2024-04. Verfasst von David G Su und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Surgical Oncology, Yale University School of Medicine, New Haven, CT. Hauptthemen laut MEDLINE: Melanoma, Receptor, Melanocortin, Type 1, Disease Progression, Skin Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Melanocortin-1 receptor (MC1R) plays a critical role in human pigmentation and DNA repair mechanisms. MC1R-targeting agents are being investigated in clinical trials in patients with melanoma, yet large studies investigating the rate and degree of MC1R expression in primary and metastatic human melanoma tissue are lacking. METHODS Using tissue microarrays containing three large cohorts of 225 cases of benign nevi, 189 with primary melanoma, and 271 with metastatic melanoma, we applied quantitative immunofluorescence and immunohistochemistry to comprehensively study MC1R protein expression. RESULTS We show a stepwise elevation of MC1R expression in different stages of melanoma progression (nevi, primary, metastasis). Higher MC1R expression was seen in deeper (>1 mm) primary lesions and ulcerated lesions and was associated with shorter survival in primary and metastatic tumors. On multivariable analysis, Breslow thickness, male sex, and chronic sun exposure were independent predictors of worse overall survival in the primary melanoma cohort. CONCLUSION Our data suggest that MC1R might be a valuable drug target in aggressive melanoma. Additional studies are warranted to determine its functional significance in melanoma progression and its utility as a predictive biomarker in patients receiving MC1R-directed therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaReceptor, Melanocortin, Type 1Disease ProgressionSkin NeoplasmsBiomarkers, TumorHumansMaleFemaleMiddle AgedAgedAdult

Substanzen

Receptor, Melanocortin, Type 1MC1R protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Division of Surgical Oncology, Yale University School of Medicine, New Haven, CT.
  • Division of Medical Oncology, Yale University School of Medicine, New Haven, CT.
  • Department of Radiology, Division of Advanced Medical Imaging Research, University of Alabama at Birmingham, Birmingham, AL.

ORCID-Profile: David G Su, David Schoenfeld, Bernadette Marquez-Nostra, Kelly Olino, Harriet Kluger

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Su, D. G., Djureinovic, D., Schoenfeld, D., Marquez-Nostra, B., Olino, K., Jilaveanu, L., & Kluger, H. (2024). Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma. JCO Precision Oncology. https://doi.org/10.1200/po.23.00702

Vancouver

Su DG, Djureinovic D, Schoenfeld D, Marquez-Nostra B, Olino K, Jilaveanu L, et al. Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma. JCO Precision Oncology. 2024. doi:10.1200/po.23.00702

BibTeX
@article{Su2024,
  author = {Su, David G and Djureinovic, Dijana and Schoenfeld, David and Marquez-Nostra, Bernadette and Olino, Kelly and Jilaveanu, Lucia and Kluger, Harriet},
  title = {Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma},
  journal = {JCO Precision Oncology},
  year = {2024},
  number = {8},
  doi = {10.1200/po.23.00702}
}
Kostenlos starten →